What is Aldeyra Therapeutics Inc's earnings per share (EPS)?

Aldeyra Therapeutics Inc (ALDX) reported diluted earnings per share of -$0.56 for fiscal year 2025. This represents a 40.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aldeyra Therapeutics Inc (ALDX) Financials

ALDX

FY2025 annual

Revenue Not reported for FY2025

Net Income -$33.8M +39.4% YoY

EPS (Diluted) -$0.56 +40.4% YoY

Operating Cash Flow -$33.3M +22.8% YoY

Market Cap $92.9M as of Sep 9, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 2.5x on $37.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALDX SEC filings page.

This page shows Aldeyra Therapeutics Inc (ALDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ALDX FY2025 2026-08-30

Aldeyra’s dominant mechanic is development spending: 2025 losses narrowed as research investment and debt both receded.

The 2025 operating loss narrowed to $35.3M from $60.1M in FY2024, while operating cash flow also improved. Operating cash flow remained close to that loss, while R&D fell to $25.7M from $48.2M, so the improvement is better read as reduced development spend than operating scale.

R&D was 2.7x SG&A in FY2025, so expense concentration remains in development rather than administration.

Total assets fell to $72.1M in FY2025 from $104.6M in FY2024, indicating contraction in the resource base supporting research. Debt-to-equity was 0.0x, while reported liquidity equaled 25.2 months of annual operating outflow at FY2025 year-end; the current ratio has nevertheless compressed across the reported periods.

Financial Health Signals

Financial health score not available

Aldeyra Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/7

Aldeyra Therapeutics Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Aldeyra Therapeutics Inc reported a net loss of $33.8M while operations used $33.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Aldeyra Therapeutics Inc reported an operating loss of $35.3M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$5.8M

YoY+42.8%

QoQ-66.1%

Aldeyra Therapeutics Inc's EBITDA was -$5.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.8% from the same quarter a year earlier. Against the prior quarter it is down 66.1%.

Net Income

-$5.5M

YoY+44.2%

QoQ-57.9%

Aldeyra Therapeutics Inc reported -$5.5M in net income in Q2 2026. This represents an increase of 44.2% from the same quarter a year earlier. Against the prior quarter it is down 57.9%.

EPS (Diluted)

-$0.09

YoY+43.8%

QoQ-50.0%

Aldeyra Therapeutics Inc earned -$0.09 per diluted share (EPS) in Q2 2026. This represents an increase of 43.8% from the same quarter a year earlier. Against the prior quarter it is down 50.0%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$45.1M

YoY+9.3%

QoQ-30.6%

5Y CAGR-29.0%

10Y CAGR+9.9%

Aldeyra Therapeutics Inc held $45.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

60M

YoY+0.7%

QoQ0.0%

5Y CAGR+0.8%

10Y CAGR+17.1%

Aldeyra Therapeutics Inc had 60M shares outstanding in Q2 2026. This represents an increase of 0.7% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-14.4%

YoY+3.3pp

QoQ-6.2pp

Aldeyra Therapeutics Inc's ROE was -14.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$3.5M

YoY-59.0%

QoQ+44.6%

Aldeyra Therapeutics Inc invested $3.5M in research and development in Q2 2026. This represents a decrease of 59.0% from the same quarter a year earlier. Against the prior quarter it is up 44.6%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

ALDX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ALDX quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
R&D Expenses	N/A	$25.7M-46.8%	$48.2M+63.7%	$29.5M-37.7%	$47.3M+5.3%	$44.9M+82.1%	$24.7M-44.4%	$44.4M+48.7%	$29.8M+82.9%	$16.3M+23.7%	$13.2M+74.0%	$7.6M+104.3%	$3.7M+140.5%	$1.5M	N/A	N/A
SG&A Expenses	N/A	$9.6M-19.3%	$11.9M-10.8%	$13.3M-13.3%	$15.4M+36.3%	$11.3M+13.0%	$10.0M-17.8%	$12.2M+23.1%	$9.9M+59.7%	$6.2M+12.1%	$5.5M+25.0%	$4.4M+23.9%	$3.6M+66.9%	$2.1M	N/A	N/A
Operating Income	N/A	-$35.3M+41.3%	-$60.1M-40.5%	-$42.8M+31.7%	-$62.7M-11.5%	-$56.2M-54.4%	-$36.4M+42.3%	-$63.1M-58.9%	-$39.7M-76.5%	-$22.5M-20.3%	-$18.7M-55.9%	-$12.0M-64.9%	-$7.3M-97.8%	-$3.7M	N/A	N/A
EBITDA	N/A	-$35.0M+41.5%	-$59.9M-40.8%	-$42.5M+31.9%	-$62.4M-11.6%	-$56.0M-53.9%	-$36.4M+42.3%	-$63.0M-58.9%	-$39.6M-76.5%	-$22.5M-20.3%	-$18.7M-55.9%	-$12.0M-64.7%	-$7.3M	N/A	N/A	N/A
Interest Expense	N/A	$1.9M-1.1%	$1.9M-7.0%	$2.1M+22.3%	$1.7M-2.8%	$1.7M-8.5%	$1.9M+215.3%	$604K+311.4%	$147K+29.4%	$113K+7.5%	$106K-6.1%	$112K-54.0%	$244K+53.3%	$159K	N/A	N/A
Income Tax	N/A	$0-100.0%	$1K	$0	$0	$0+100.0%	-$479K+63.4%	-$1.3M	$0	$0	$0	$0	$0	N/A	N/A	N/A
Net Income	N/A	-$33.8M+39.4%	-$55.9M-48.8%	-$37.5M+39.5%	-$62.0M-7.4%	-$57.8M-53.8%	-$37.6M+38.3%	-$60.8M-56.4%	-$38.9M-74.1%	-$22.3M-19.5%	-$18.7M-54.7%	-$12.1M-133.1%	-$5.2M-139.7%	$13.1M+156.6%	-$23.1M-870.3%	-$2.4M
EPS (Basic)	N/A	-$0.56+40.4%	-$0.94-46.9%	-$0.64+39.6%	-$1.06+0.9%	-$1.07	N/A	N/A	N/A	N/A	N/A	-$1.40+44.2%	-$2.51-171.9%	$3.49	N/A	N/A
EPS (Diluted)	-$0.38	-$0.56+40.4%	-$0.94-46.9%	-$0.64+39.6%	-$1.06+0.9%	-$1.07	N/A	N/A	N/A	N/A	N/A	-$1.40	-$3.09	-$17.61	N/A	N/A
Diluted Shares (Avg)	N/A	60M+1.0%	59M+0.9%	59M+0.9%	58M+8.1%	54M	N/A	N/A	N/A	N/A	N/A	9M	4M	855,508	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$3.5M-59.0%	$2.4M-67.5%	N/A	$5.4M-56.3%	$8.5M-43.2%	$7.4M+20.1%	N/A	$12.4M+78.7%
SG&A Expenses	$2.4M+42.2%	$1.1M-62.1%	N/A	$2.6M-30.5%	$1.7M-45.2%	$3.0M-6.4%	N/A	$3.7M+42.8%
Operating Income	-$5.9M+42.5%	-$3.5M+66.0%	N/A	-$8.0M+50.4%	-$10.2M+43.5%	-$10.4M-11.0%	N/A	-$16.1M-69.0%
EBITDA	-$5.8M+42.8%	-$3.5M+66.4%	N/A	-$7.9M+50.6%	-$10.1M+43.7%	-$10.4M-11.1%	N/A	-$16.1M-69.5%
Interest Expense	$23-100.0%	$469K-3.1%	N/A	$476K-0.7%	$471K-1.5%	$484K-3.0%	N/A	$479K-11.0%
Net Income	-$5.5M+44.2%	-$3.5M+65.2%	N/A	-$7.7M+49.1%	-$9.8M+42.0%	-$9.9M-22.9%	N/A	-$15.1M-84.6%
EPS (Basic)	-$0.09+43.8%	-$0.06+64.7%	-$0.10+63.0%	-$0.13+48.0%	-$0.16+42.9%	-$0.17-21.4%	-$0.27-237.5%	-$0.25-78.6%
EPS (Diluted)	-$0.09+43.8%	-$0.06+64.7%	-$0.10+63.0%	-$0.13+48.0%	-$0.16+42.9%	-$0.17-21.4%	-$0.27-237.5%	-$0.25-78.6%
Diluted Shares (Avg)	60M+0.5%	60M+0.7%	N/A	60M+1.0%	60M+1.1%	60M+0.8%	N/A	60M+0.9%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

ALDX Balance Sheet

ALDX quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$72.1M-31.1%	$104.6M-29.5%	$148.3M-18.2%	$181.3M-22.2%	$233.1M+179.7%	$83.4M+10.4%	$75.5M-20.6%	$95.1M+115.3%	$44.2M+75.4%	$25.2M-10.7%	$28.2M+221.0%	$8.8M+134.7%	$3.7M	N/A	N/A
Current Assets	$71.8M-31.0%	$104.1M-29.6%	$147.8M-18.3%	$181.0M-22.2%	$232.8M+180.2%	$83.1M+10.5%	$75.2M-20.7%	$94.8M+115.6%	$44.0M+74.9%	$25.1M-10.5%	$28.1M+220.6%	$8.8M+167.8%	$3.3M	N/A	N/A
Cash & Equivalents	$70.0M+28.5%	$54.5M-61.8%	$142.8M-1.1%	$144.4M-37.2%	$229.8M+195.1%	$77.9M+75.3%	$44.4M-6.2%	$47.4M+136.5%	$20.0M+66.7%	$12.0M-18.0%	$14.6M+71.8%	$8.5M+161.4%	$3.3M+166.6%	$1.2M	N/A
Short-Term Investments	$0-100.0%	$46.6M	$0-100.0%	$29.9M	$0	$0-100.0%	$28.9M-37.4%	$46.2M+101.7%	$22.9M+77.7%	$12.9M-0.3%	$12.9M	$0	$0	$0	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Total Liabilities	$27.8M-17.2%	$33.6M+17.8%	$28.5M-5.8%	$30.3M+10.5%	$27.4M+14.9%	$23.8M-13.1%	$27.4M+223.8%	$8.5M+85.2%	$4.6M+29.3%	$3.5M+6.4%	$3.3M+32.9%	$2.5M-94.3%	$44.0M	N/A	N/A
Current Liabilities	$27.8M+49.5%	$18.6M-16.4%	$22.3M+44.9%	$15.4M+30.5%	$11.8M-5.1%	$12.4M-3.9%	$12.9M+52.3%	$8.5M+152.6%	$3.4M+45.9%	$2.3M+8.7%	$2.1M+59.3%	$1.3M+119.4%	$605K	N/A	N/A
Non-Current Liabilities	$0-100.0%	$15.0M+139.2%	$6.3M-58.0%	$14.9M-4.5%	$15.6M+36.7%	$11.4M-21.3%	$14.5M	$0-100.0%	$1.2M-1.5%	$1.2M+2.3%	$1.2M+3.0%	$1.2M-97.3%	$43.4M	N/A	N/A
Long-Term Debt	$0-100.0%	$15.0M	N/A	$14.9M-3.7%	$15.5M+35.6%	$11.4M-21.3%	$14.5M	N/A	$1.2M-1.5%	$1.2M+2.3%	$1.2M+3.0%	$1.2M+4.1%	$1.1M	N/A	N/A
Total Equity	$44.3M-37.7%	$71.0M-40.7%	$119.8M-20.7%	$151.0M-26.6%	$205.7M+245.7%	$59.5M+23.8%	$48.1M-44.5%	$86.6M+118.7%	$39.6M+82.9%	$21.6M-13.0%	$24.9M+295.9%	$6.3M+115.6%	-$40.2M+26.0%	-$54.4M-250.6%	-$15.5M
Retained Earnings	-$484.0M-7.5%	-$450.1M-14.2%	-$394.3M-10.5%	-$356.7M-21.0%	-$294.7M-24.4%	-$236.9M-18.8%	-$199.4M-43.9%	-$138.5M-39.0%	-$99.6M-28.9%	-$77.3M-31.9%	-$58.6M-26.0%	-$46.5M-12.6%	-$41.3M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$47.5M-44.0%	$66.5M-28.7%	$72.1M-31.1%	$77.8M-33.7%	$85.0M-32.6%	$93.2M-34.0%	$104.6M-29.5%	$117.3M-20.3%
Current Assets	$47.4M-44.0%	$66.3M-28.5%	$71.8M-31.0%	$77.5M-33.6%	$84.6M-32.7%	$92.7M-34.2%	$104.1M-29.6%	$116.7M-20.7%
Cash & Equivalents	$45.1M+9.3%	$65.0M+29.1%	$70.0M+28.5%	$59.3M-12.9%	$41.2M-41.9%	$50.4M-50.9%	$54.5M-61.8%	$68.1M-52.5%
Short-Term Investments	$0-100.0%	$0-100.0%	$0-100.0%	$16.0M-64.2%	$40.7M-17.5%	$39.7M+30.0%	$46.6M	$44.6M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$9.7M-67.5%	$24.3M-17.8%	$27.8M-17.2%	$28.6M-11.4%	$29.7M+7.0%	$29.6M+6.1%	$33.6M+17.8%	$32.2M+32.7%
Current Liabilities	$9.7M-67.3%	$24.3M+70.3%	$27.8M+49.5%	$28.5M+66.1%	$29.5M+7.0%	$14.3M-34.1%	$18.6M-16.4%	$17.2M-20.6%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$0-100.0%	$73K-99.5%	$143K+3.3%	$15.3M+146.7%	$15.0M+139.2%	$15.1M+467.1%
Long-Term Debt	N/A	$0-100.0%	$0-100.0%	$0-100.0%	$0	$15.1M	$15.0M	$15.0M+464.5%
Total Equity	$37.9M-31.5%	$42.2M-33.7%	$44.3M-37.7%	$49.2M-42.1%	$55.3M-43.8%	$63.6M-43.9%	$71.0M-40.7%	$85.1M-30.8%
Retained Earnings	-$492.9M-4.9%	-$487.4M-5.9%	-$484.0M-7.5%	-$477.5M-9.9%	-$469.8M-12.1%	-$460.0M-14.3%	-$450.1M-14.2%	-$434.3M-11.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

ALDX Cash Flow Statement

ALDX quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$22.0M	-$33.3M+22.8%	-$43.2M-42.5%	-$30.3M+46.5%	-$56.6M-33.1%	-$42.6M-13.5%	-$37.5M+16.7%	-$45.0M-50.7%	-$29.9M-55.3%	-$19.2M-26.9%	-$15.1M-62.7%	-$9.3M-95.0%	-$4.8M-179.9%	-$1.7M	N/A	N/A
Depreciation & Amortization	N/A	$252K+0.9%	$250K-5.0%	$263K+1.6%	$259K-2.1%	$264K+369.9%	$56K-41.6%	$96K+35.6%	$71K+87.6%	$38K+5.7%	$36K+90.6%	$19K+1656.6%	$1K	N/A	N/A	N/A
Stock-Based Compensation	N/A	$6.1M-23.6%	$8.0M+38.6%	$5.8M-30.6%	$8.3M+16.6%	$7.1M+0.3%	$7.1M-12.4%	$8.1M+95.0%	$4.1M+52.7%	$2.7M-1.6%	$2.8M+26.2%	$2.2M+7.4%	$2.0M+19.7%	$1.7M	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$16K+109.0%	$8K	N/A	$10K-96.4%	$263K+962.1%	$25K+109.6%	$12K-86.3%	$86K+512.4%	$14K	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	-$30.3M+46.5%	-$56.7M-33.1%	-$42.6M	N/A	-$45.0M-49.4%	-$30.1M-56.5%	-$19.2M-27.0%	-$15.2M-61.3%	-$9.4M-96.2%	-$4.8M	N/A	N/A	N/A
Investing Cash Flow	$41.0M	$47.7M+206.3%	-$44.9M-249.7%	$30.0M+200.2%	-$30.0M-383637.3%	-$8K-100.0%	$29.0M+57.1%	$18.5M+179.2%	-$23.3M-128.8%	-$10.2M	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$15.1M	$1.1M+755.4%	-$171K+86.5%	-$1.3M-204.1%	$1.2M-99.4%	$194.5M+364.2%	$41.9M+77.7%	$23.6M-70.7%	$80.5M+115.1%	$37.4M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$4.6M+46.4%	-$5.1M+59.0%	-$5.3M+56.0%	-$7.0M+12.0%	-$8.6M+35.3%	-$12.5M-25.0%	-$12.0M-2505.3%	-$8.0M+0.6%
Depreciation & Amortization	$71K+13.5%	$67K+9.3%	$65K+1.2%	$64K+1.1%	$62K+1.1%	$61K+0.5%	$64K-3.2%	$63K-3.1%
Stock-Based Compensation	$1.6M+735.9%	-$988K-144.4%	N/A	$2.6M-20.0%	$197K-89.8%	$2.2M+43.6%	N/A	$3.2M+308.7%
Investing Cash Flow	-$23K+95.8%	$0-100.0%	$16.0M+1123.1%	$25.0M+375.0%	-$554K+97.0%	$7.3M+124.0%	-$1.6M	$5.3M
Financing Cash Flow	-$15.3M	$71K-92.9%	$0-100.0%	$121K+161.2%	$0	$1.0M+5412.7%	$8K+100.8%	-$197K+37.5%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

ALDX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ALDX quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Return on Equity	-76.5%+2.2pp	-78.7%-47.3pp	-31.3%+9.7pp	-41.1%-13.0pp	-28.1%+35.0pp	-63.1%+63.4pp	-126.5%-81.6pp	-44.9%+11.5pp	-56.4%+30.0pp	-86.4%-37.8pp	-48.6%+34.0pp	-82.5%	N/A	N/A	N/A
Return on Assets	-47.0%+6.4pp	-53.4%-28.1pp	-25.3%+8.9pp	-34.2%-9.4pp	-24.8%+20.3pp	-45.1%+35.5pp	-80.5%-39.6pp	-40.9%+9.7pp	-50.6%+23.7pp	-74.2%-31.4pp	-42.9%+16.2pp	-59.0%-407.9pp	348.9%	N/A	N/A
Current Ratio	2.58-3.0x	5.59-1.0x	6.64-5.1x	11.78-8.0x	19.77+13.1x	6.69+0.9x	5.82-5.4x	11.18-1.9x	13.11+2.2x	10.93-2.3x	13.28+6.7x	6.60+1.2x	5.41	N/A	N/A
Debt-to-Equity	0.00-0.2x	0.210.0x	0.24+0.1x	0.100.0x	0.08-0.1x	0.19-0.1x	0.30+0.2x	0.10+0.1x	0.030.0x	0.060.0x	0.05-0.1x	0.19	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-14.4%+3.3pp	-8.2%+7.4pp	N/A	-15.6%+2.2pp	-17.7%-0.5pp	-15.6%-8.5pp	N/A	-17.8%-11.1pp
Return on Assets	-11.5%0.0pp	-5.2%+5.5pp	N/A	-9.9%+3.0pp	-11.5%+1.9pp	-10.7%-4.9pp	N/A	-12.9%-7.3pp
Current Ratio	4.91+2.0x	2.72-3.8x	2.58-3.0x	2.72-4.1x	2.86-1.7x	6.490.0x	5.59-1.0x	6.800.0x
Debt-to-Equity	0.25+0.3x	0.00-0.2x	0.00-0.2x	0.00-0.2x	0.000.0x	0.24+0.2x	0.21+0.2x	0.18+0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Aldeyra Therapeutics Inc ALDX	FY2025	N/A	-$33.8M	N/A	$92.9M	—
Contineum Therapeutics CTNM	FY2025	N/A	-$60.0M	N/A	$599.7M	—
I-Mab IMAB	FY2025	N/A	-$46.3M	N/A	$533.7M	—
Tectonic Therapeutic Inc TECX	FY2025	N/A	N/A	N/A	$594.3M	—
MBX Biosciences Inc MBX	FY2025	N/A	-$87.0M	N/A	$3.0B	—
4D Molecular Therapeutics Inc. FDMT	FY2025	$85.2M	-$140.1M	N/A	$808.2M	72/100

Where Aldeyra Therapeutics Inc Ranks

Frequently Asked Questions

Is Aldeyra Therapeutics Inc profitable?

No, Aldeyra Therapeutics Inc (ALDX) reported a net income of -$33.8M in fiscal year 2025.

What is Aldeyra Therapeutics Inc's EBITDA?

Aldeyra Therapeutics Inc (ALDX) had EBITDA of -$35.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Aldeyra Therapeutics Inc have?

As of fiscal year 2025, Aldeyra Therapeutics Inc (ALDX) had $70.0M in cash and equivalents against $0 in long-term debt.

What is Aldeyra Therapeutics Inc's return on equity (ROE)?

Aldeyra Therapeutics Inc (ALDX) has a return on equity of -76.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Aldeyra Therapeutics Inc's operating cash flow?

Aldeyra Therapeutics Inc (ALDX) recorded an outflow of $33.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Aldeyra Therapeutics Inc's total assets?

Aldeyra Therapeutics Inc (ALDX) had $72.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Aldeyra Therapeutics Inc spend on research and development?

Aldeyra Therapeutics Inc (ALDX) invested $25.7M in research and development during fiscal year 2025.

How many shares does Aldeyra Therapeutics Inc have outstanding?

Aldeyra Therapeutics Inc (ALDX) had 60M shares outstanding as of fiscal year 2025.

What is Aldeyra Therapeutics Inc's current ratio?

Aldeyra Therapeutics Inc (ALDX) had a current ratio of 2.58 as of fiscal year 2025, which is generally considered healthy.

What is Aldeyra Therapeutics Inc's debt-to-equity ratio?

Aldeyra Therapeutics Inc (ALDX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aldeyra Therapeutics Inc's return on assets (ROA)?

Aldeyra Therapeutics Inc (ALDX) had a return on assets of -47.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aldeyra Therapeutics Inc's P/E ratio?

Aldeyra Therapeutics Inc (ALDX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $92.9M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Aldeyra Therapeutics Inc's price-to-sales ratio?

Aldeyra Therapeutics Inc (ALDX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $92.9M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Aldeyra Therapeutics Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Aldeyra Therapeutics Inc (ALDX) held $70.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $33.3M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Aldeyra Therapeutics Inc's Piotroski F-Score?

Aldeyra Therapeutics Inc (ALDX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aldeyra Therapeutics Inc's earnings high quality?

Aldeyra Therapeutics Inc (ALDX) reported a net loss of $33.8M while operations used $33.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Aldeyra Therapeutics Inc cover its interest payments?

Aldeyra Therapeutics Inc (ALDX) reported an operating loss of $35.3M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.